Zobrazeno 1 - 9
of 9
pro vyhledávání: ''
Autor:
Satoshi Yamashita, Naoko Hattori, Yuki Kurahashi, Toshikazu Ushijima, Naoko Sueoka-Aragane, Tatsuro Watanabe, Akemi Sato, Kensuke Kojima, Hideaki Nakamura, Atsushi Kawaguchi, Shinya Kimura, Eisaburo Sueoka, Nao Yoshida, Kazuharu Kamachi, Seiji Okada, Hiroshi Ureshino, Yuki Fukuda-Kurahashi
Publikováno v:
Blood. 136:871-884
Adult T-cell leukemia-lymphoma (ATL) is an aggressive hematological malignancy of CD4+ T cells transformed by human T-cell lymphotropic virus-1 (HTLV-1). Most HTLV-1–infected individuals are asymptomatic, and only 3% to 5% of carriers develop ATL.
Autor:
Ester B. M. Remmerswaal, Arnon P. Kater, Iris de Weerdt, Ineke J. M. ten Berge, Tom Hofland, Perry D. Moerland, Nora Liu, Laura M. Faber, Roeland Lameris, Mark-David Levin, Mario van der Stelt, Sanne Endstra, Sanne H. Tonino, Hans van Vliet, Aldo Jongejan, Renée C.G. de Bruin, Eric Eldering, Tanja D. de Gruijl
Publikováno v:
Blood
de Weerdt, I, Hofland, T, Lameris, R, Endstra, S, Jongejan, A, Moerland, P D, de Bruin, R C G, Remmerswaal, E B M, Ten Berge, I J M, Liu, N, van der Stelt, M, Faber, L M, Levin, M-D, Eldering, E, Tonino, S H, de Gruijl, T D, van der Vliet, H J & Kater, A P 2018, ' Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib ', Blood, vol. 132, no. 21, pp. 2260-2272 . https://doi.org/10.1182/blood-2017-12-822569
Blood, 132(21), 2260-2272
Blood, 132(21), 2260-2272. American Society of Hematology
de Weerdt, I, Hofland, T, Lameris, R, Endstra, S, Jongejan, A, Moerland, P D, de Bruin, R C G, Remmerswaal, E B M, Ten Berge, I J M, Liu, N, van der Stelt, M, Faber, L M, Levin, M-D, Eldering, E, Tonino, S H, de Gruijl, T D, van der Vliet, H J & Kater, A P 2018, ' Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib ', Blood, vol. 132, no. 21, pp. 2260-2272 . https://doi.org/10.1182/blood-2017-12-822569
Blood, 132(21), 2260-2272
Blood, 132(21), 2260-2272. American Society of Hematology
The efficacy of autologous (αβ) T-cell–based treatment strategies in chronic lymphocytic leukemia (CLL) has been modest. The Vγ9Vδ2-T cell subset consists of cytotoxic T lymphocytes with potent antilymphoma activity via a major histocompatibili
Autor:
James O. Lindsay, Maria Calaminci, Matt Mee, John G. Gribben, Jamie D. Cavenagh, James Aries, Jennifer A. Ball, Andrew J. Stagg, Sarah Charrot, Andrew Clear, Jeff K. Davies, Caroline Besley
Publikováno v:
Blood. 137(5)
Gastrointestinal (GI) graft-versus-host disease (GVHD) is a major barrier in allogeneic hematopoietic stem cell transplantation (allo-HSCT). The metabolite retinoic acid (RA) potentiates GI-GVHD in mice via alloreactive T cells expressing the RA rece
Autor:
Anna Cabrelle, Renato Zambello, Veronica Martini, Federica Frezzato, Antonella Teramo, Elisa Boscaro, Livio Trentin, Francesco Piazza, Cristina Gattazzo, Elisa Ave, Valentina Trimarco, Francesca Passeri, Albana Lico, Monica Facco, Gianpietro Semenzato, Giulia Tasca
Publikováno v:
Blood. 121:3843-3854
The JAK/STAT pathway is altered in T-cell large granular lymphocytic leukemia. In all patients, leukemic LGLs display upregulation of phosphorylated STAT3 (P-STAT3) that activates expression of many antiapoptotic genes. To investigate the mechanisms
Publikováno v:
Blood. 114:5201-5205
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by proliferation of one or more myeloid cell lineages. Some patients exhibit leukemic transformation (LT) by unknown mechanisms, and chemotherapy may incre
Autor:
David J. McConkey, Kenneth Dunner, Peng Huang, Yelena V. Krupnik, Jennifer S. Carew, Steffan T. Nawrocki, Michael J. Keating
Publikováno v:
Blood. 107:222-231
Previous studies showed that chronic lymphocytic leukemia (CLL) cells exhibit certain mitochondrial abnormalities including mtDNA mutations, increased superoxide generation, and aberrant mitochondrial biogenesis, which are associated with impaired ap
Autor:
Charles L. Sawyers, Feiyu Zhang, Stephen J. Forman, Ravi Bhatia, Melissa Holtz, Marilyn L. Slovak
Publikováno v:
Blood. 99:3792-3800
Imatinib mesylate (STI571) is a promising new treatment for chronic myelogenous leukemia (CML). The effect of imatinib mesylate on primitive malignant progenitors in CML has not been evaluated, and it is not clear whether suppression of progenitor gr
Autor:
Nicole Casadevall, Françoise Wendling, Stéphane Giraudier, Jean-Pierre Le Couedic, André Katz, William Vainchenker, Anne Laure Taksin, Najet Debili, Aline Massé, Isabelle Dusanter-Fourt
Publikováno v:
ResearcherID
Essential thrombocythemia (ET) and idiopathic myelofibrosis (PMF) are two myeloproliferative diseases characterized by a marked megakaryocytic (MK) involvement. The pathogenesis of these two diseases is unknown. Recently it has been shown that overex
Autor:
Mercè de Frias, Joan Gil, Antonio F. Santidrian, Ana M. Cosialls, Benoit Viollet, Eva González-Barca, Llorenç Coll-Mulet, Diana M. González-Gironès, Verena Labi, Daniel Iglesias-Serret, Gabriel Pons, Clara Campàs, Andreas Villunger, Esther Alonso, Adalberto Benito
Publikováno v:
Blood. 116(16)
5-Aminoimidazole-4-carboxamide riboside or acadesine (AICAR) induces apoptosis in chronic lymphocytic leukemia (CLL) cells. A clinical study of AICAR is currently being performed in patients with this disease. Here, we have analyzed the mechanisms in